Efficiency in Drug Discovery: Liver S9 Fraction Assay As a Screen for Metabolic Stability
TLDR
Replacing liver microsome and hepatocyte assays with S9 assay for high throughput metabolic screening purposes provides the combined benefit of comprehensive and high quality data at a reasonable expense for drug discovery programs.Abstract:
Background A rapid and comprehensive metabolic stability screen at the top of a drug discovery flow chart serves as an effective gate in eliminating low value compounds. This imparts a significant level of efficiency and saves valuable resources. While microsomes are amenable to high throughput automation and are cost effective, their enzymatic make-up is limited to that which is contained in endoplasmic reticulum, thereby informing only on Phase I metabolism. Lack of Phase II metabolism data can become a potential liability later in the process, adversely affecting discovery projects' timelines and budget. Hepatocytes offer a full complement of metabolic enzymes and retain their cellular compartments, better representing liver metabolic function. However, hepatocyte screens are relatively expensive, labor intensive, and not easily automatable. Liver S9 fractions include Phase I and II metabolic enzymes, are relatively inexpensive, easy to use, and amenable to automation, making them a more appropriate screening system. We compare the data from the three systems and present the results. Results Liver S9 and hepatocyte stability assays binned into the same category 70-84% of the time. Microsome and hepatocyte data were in agreement 73-82% of the time. The true rate for stability versus plasma clearance was 45% for hepatocytes and 43% for S9. Conclusion In our opinion, replacing liver microsome and hepatocyte assays with S9 assay for high throughput metabolic screening purposes provides the combined benefit of comprehensive and high quality data at a reasonable expense for drug discovery programs.read more
Citations
More filters
Journal ArticleDOI
Label-free absolute protein quantification with data-independent acquisition
TL;DR: A novel DIA method using the TPA algorithm (DIA-TPA) for the absolute quantification of protein expressions in human liver microsomal and S9 samples with the capability absolutely quantifying proteins with shared peptides.
Journal ArticleDOI
The Clock Protein Bmal1 Regulates Circadian Expression and Activity of Sulfotransferase 1a1 in Mice
TL;DR: A potential role of the clock protein Bmal1 (brain and muscle Arnt-like protein-1) in circadian regulation of Sult1a1 in mice was investigated and it was shown that hepatic Sult 1a1 was rhythmically expressed at both mRNA and protein levels.
Journal ArticleDOI
The safety evaluation of food flavoring substances: the role of genotoxicity studies.
Nigel J. Gooderham,Samuel M. Cohen,Gerhard Eisenbrand,Shoji Fukushima,F. Peter Guengerich,Stephen S. Hecht,Ivonne M.C.M. Rietjens,Thomas J. Rosol,Maria Bastaki,Matthew J. Linman,Sean V. Taylor +10 more
TL;DR: The weight of evidence approach adopted by the FEMA Expert Panel leads to a rational assessment of risk associated with consumer intake of flavoring substances under the conditions of use.
Journal ArticleDOI
Exposure levels, determinants and risk assessment of organophosphate flame retardants and plasticizers in adolescents (14-15 years) from the Flemish Environment and Health Study.
Michiel Bastiaensen,Celine Gys,Ann Colles,Veerle Verheyen,Gudrun Koppen,Eva Govarts,Liesbeth Bruckers,Bert Morrens,Ilse Loots,Annelies De Decker,Vera Nelen,Tim S. Nawrot,Stefaan De Henauw,Nik van Larebeke,Greet Schoeters,Adrian Covaci +15 more
TL;DR: This is the first report on internal exposure to seven commonly used PFRs in a European population and suggests that the associated risk is low at present.
Journal ArticleDOI
Drug metabolic stability in early drug discovery to develop potential lead compounds.
TL;DR: In this paper, a review summarises all the recent approaches and technological advancements in metabolic stability studies for narrowing down the potential lead compounds in drug discovery and summarises the potential pitfalls and assumptions made during the in vivo intrinsic clearance estimation from in vitro intrinsic clearance.
References
More filters
Journal ArticleDOI
Screening for human ADME/Tox drug properties in drug discovery
TL;DR: In this review, the methodologies that are available for use in drug development as in vitro human-based screens for ADME/Tox drug properties are discussed.
Journal ArticleDOI
Strategies for using in vitro screens in drug metabolism.
TL;DR: A review of the systems currently employed shows that, whereas all systems have their own caveats, it is possible to find an appropriate system for any particular question that is asked.
Journal ArticleDOI
Drug metabolism and pharmacokinetics.
Margherita Strolin Benedetti,Rhys Whomsley,Italo Poggesi,Willi Cawello,François-Xavier Mathy,Marie-Laure Delporte,Peggy Papeleu,Jean-Baptiste Watelet +7 more
TL;DR: As marketed antiallergic drugs include both racemates and enantiomers, aspects of stereoselective absorption, distribution, metabolism, and excretion have been discussed and a new and promising methodology, microdosing, has been presented.
Journal ArticleDOI
Functionality of cultured human hepatocytes from elective samples, cadaveric grafts and hepatectomies
TL;DR: The better functionality and the higher accessibility of elective liver samples in comparison to the other groups suggest this source of liver tissue as the most appropriate for cell harvesting purposes.
Related Papers (5)
The conduct of drug metabolism studies considered good practice (II): in vitro experiments.
Lee Jia,Xiaodong Liu +1 more